Europe — EMA

Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

Bacillus Calmette-Guérin (BCG), the active ingredient in Oncotice, is a live attenuated bacterial immunotherapy presented as a suspension for intravesical use. It treats non‑muscle‑invasive bladder cancer in adults.

Bacillus Calmette-Guérin (Bcg), Tice

Request sourcing

Pack/s

What is Bacillus Calmette-Guérin (Bcg), Tice?

GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

What is Bacillus Calmette-Guérin (Bcg), Tice used for?

Oncotice is a BCG‑based immunotherapy that acts on the urothelial carcinoma pathway. - Non‑muscle‑invasive bladder cancer: reduces the risk of tumour recurrence and progression. - Carcinoma in situ (CIS) of the bladder: helps to achieve complete remission remission as an adjunct to surgical resection. - High‑risk grade 3 tumours of the bladder : provides ad ‑ un‑ un un un un un un un un un un un un un un un un un un un un un un un un un

What are the side effects of Bacillus Calmette-Guérin (Bcg), Tice?

Side effects are generally ...

Common Side Effects: - ... - ....

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →